Incannex Healthcare Ltd ADR - Asset Resilience Ratio
Incannex Healthcare Ltd ADR (IXHL) has an Asset Resilience Ratio of 0.06% as of March 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how liquid is Incannex Healthcare Ltd ADR's working capital to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2010–2017)
This chart shows how Incannex Healthcare Ltd ADR's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see balance sheet size of Incannex Healthcare Ltd ADR.
Liquid Assets Composition Over Time
This chart breaks down Incannex Healthcare Ltd ADR's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore IXHL long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $5.28K | 0.06% |
| Total Liquid Assets | $5.28K | 0.06% |
Asset Resilience Insights
- Limited Liquidity: Incannex Healthcare Ltd ADR maintains only 0.06% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Incannex Healthcare Ltd ADR Industry Peers by Asset Resilience Ratio
Compare Incannex Healthcare Ltd ADR's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Beijing Tongrentang Co Ltd
SHG:600085 |
Drug Manufacturers - Specialty & Generic | 0.50% |
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Neuland Laboratories Limited
NSE:NEULANDLAB |
Drug Manufacturers - Specialty & Generic | 9.65% |
|
China Resources Double-Crane Pharmaceutical Co Ltd
SHG:600062 |
Drug Manufacturers - Specialty & Generic | 1.18% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.01% |
Annual Asset Resilience Ratio for Incannex Healthcare Ltd ADR (2010–2017)
The table below shows the annual Asset Resilience Ratio data for Incannex Healthcare Ltd ADR.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2017-06-30 | 16.59% | $166.58K | $1.00 Million | +16.26pp |
| 2015-06-30 | 0.34% | $21.32K | $6.30 Million | -5.90pp |
| 2010-06-30 | 6.24% | $1.00 Million | $16.05 Million | -- |
About Incannex Healthcare Ltd ADR
Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synth… Read more